Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vancomycin

FDA-approved product (solution, intravenous, oral), marketed as Vancomycin, Firvanq Kit, Tyzavan and 5 more.

Registered studies
50+
Lab records
118
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vancomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Diarrhea
  • Endocarditis
  • Enterocolitis
  • Eye infection
  • Infection
  • Infective endocarditis
  • Respiratory tract infectious disorder
  • Sepsis
  • Skin disease
  • Skin infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Glycopeptide antibacterials
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XA01; WHO ATC A07AA09; WHO ATC S01AA28

Repurposing investigation

Vancomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli78.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae80.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 103 of 103 lab records
  • E. coli: measured active in 8 of 9 lab records
  • K. pneumoniae: measured active in 2 of 3 lab records
  • M. tuberculosis: measured active in 0 of 3 lab records
Open Vancomycin in ChEMBL Registered studies below
Show the 118 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vancomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

    NCT00107978 · start 2005-02

    Registered record
    Registry ID
    NCT00107978
    Conditions
    Staphylococcal Skin Infection
    Interventions
    Telavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2006-05
    Enrolment
    1,035

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Skin Infection
    InterventionTelavancin; Vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

    NCT00091819 · start 2005-01

    Registered record
    Registry ID
    NCT00091819
    Conditions
    Staphylococcal Skin Infection
    Interventions
    Telavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2006-06
    Enrolment
    862

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Skin Infection
    InterventionTelavancin; Vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

    NCT00167960 · start 2005-01

    Registered record
    Registry ID
    NCT00167960
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    Piperacillin/tazobactam and other β-lactam/β-lactamase
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-01
    Completion
    Not recorded
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    InterventionPiperacillin/tazobactam and other β-lactam/β-lactamase
    PhaseNot recorded
    Registry statusCompleted

  • Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

    NCT00079976 · start 2003-10

    Registered record
    Registry ID
    NCT00079976
    Conditions
    Gram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance
    Interventions
    Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-06
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance
    InterventionTigecycline
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

    NCT00035425 · start 2001-11

    Registered record
    Registry ID
    NCT00035425
    Conditions
    Febrile Neutropenia
    Interventions
    linezolid; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2002-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    Interventionlinezolid; vancomycin
    PhasePhase 3
    Registry statusCompleted